Vice President, Regulatory Affairs
Shirley Clift has served as Vice President, Regulatory Affairs since joining Sangamo in January 2010. Ms. Clift has over twenty years of biotechnology management experience in global regulatory affairs and cell and gene therapy product development. Throughout her career, she has been responsible for multiple corporate sponsored regulatory filings in the U.S., Europe, Japan, and Australia. Prior to joining Sangamo, Ms. Clift held various positions at Cell Genesys, Inc., including Vice President, Regulatory Affairs. Prior to joining Cell Genesys, Inc. in 1997, she held a variety of positions at Somatix Therapy Corp. Earlier in her career, she held various basic research positions at Lawrence Berkeley Laboratory, Genentech, Baylor College of Medicine, University of California, San Francisco, and Universidad Nacional Autonoma De Mexico. Ms. Clift received her B.A. degree from the University of California, Berkeley.Less
Senior Vice President and CMO
Edward Conner, M.D. has served as Senior Vice President and Chief Medical Officer since November 2016. He has over 10 years of industry experience in early and late stage clinical development in a broad range of disease areas including rare diseases, oncology and infectious diseases. Prior to joining Sangamo, Dr. Conner served as Vice President, Clinical Sciences at Ultragenyx Pharmaceuticals, a biopharmaceutical company developing novel products for the treatment of rare and ultra-rare diseases. Prior to joining Ultragenyx, he served as Senior Medical Director at BioMarin Pharmaceuticals Inc., where he led protocol development and regulatory interaction for its global phase 3 program in Pompe disease. From 2008 to 2013, Dr. Conner served as Medical Director at Genentech and was the clinical science team leader of two product candidates, including Xolair®, which is now a commercial drug product. He completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology & Allergic Diseases at Johns Hopkins School of Medicine. He received a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.Less
Vice President, Product Development and Management
Nathalie Dubois-Stringfellow, Ph.D., has served as Vice President, Product Development and Management since January 2015 and oversees the development and execution of project team strategy for Sangamo’s ZFP therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV and Huntington’s disease. She has over 20 years of experience implementing and managing preclinical and clinical development of biologic therapies in oncology, as well as immune, infectious and genetic diseases. Dr. Dubois-Stringfellow joined Sangamo in January 2011 as Senior Director, Project Management. Prior to joining Sangamo, she held various positions in Discovery Research, Preclinical Research, Project Management, Clinical Development, and Portfolio Management at Chiron Corp., Bayer Corp., Signature Biosciences, Inc. and most recently XOMA LLC, where she served as Senior Director, Preclinical Portfolio and Alliance Management. Dr. Dubois-Stringfellow was a post-doctoral fellow at the University of North Carolina, Chapel Hill, where she studied angiogenesis and tumorigenesis in transgenic mice and cell culture systems. She received her M.S. in Genetics and Immunology, and her Ph.D. in Human Genetics from the Université Pierre et Marie Curie in Paris, France.Less
Vice President, Technical Operations
Mohammad El-Kalay, Ph.D., has served as Vice President, Technical Operations since August 2016. Dr. El-Kalay has over 25 years of experience in the biotechnology industry with significant expertise in process development and cGMP manufacturing of biotherapeutics, including hematopoietic stem cells, mesenchymal stem cells, T-cells and neural stem cells. Prior to joining Sangamo, Dr. El-Kalay was Vice President, Process Development & Manufacturing at StemCells, Inc., a company developing allogeneic neural stem cells for the treatment of CNS diseases. In 2006, Dr. El-Kalay founded and served as President and Chief Executive Officer of EyeCyte, Inc. a biotherapeutics company focused on the development of autologous cell therapies to treat various retinal diseases. From 2000 to 2007, Dr. El-Kalay held leadership positions at several cell therapy companies, including Senior Vice President, Process Development at Telos Pharmaceuticals LLC; Vice President, Research & Development at MicroIslet, Inc.; and Vice President, Product & Process Development at MorphoGen Pharmacueticals, Inc., a pluripotent stem cell company. Dr. El-Kalay received his B.Sc. in Chemical Engineering and Ph.D. in Biomedical Engineering from Strathclyde University in Glasgow, UK.Less
Chief of Staff
Heather Erickson has served as Chief of Staff since July 2016 and is responsible for the execution of Sangamo's daily operations and special projects. Prior to joining Sangamo, Ms. Erickson served as the President and CEO of the Life Sciences Foundation, a national research and education foundation focused on collecting and organizing the story of biotechnology and providing audiences with context for the role the life sciences play in society. From 2004 to 2012, Ms. Erickson founded and served as President of the MedTech Association, leading the industry trade organization to become the hub of Upstate New York’s bioscience and medical technology industry, with nearly 100 member companies and universities across the state, including Fortune 500 corporations. Prior to founding MedTech, she served as Senior Consultant at the San Francisco headquarters of Edgar, Dunn & Company, an international management consultancy specializing in strategic planning for the financial services industry. Ms. Erickson received a B.S. in Molecular, Cellular and Developmental Biology from Yale University.Less
Senior Vice President and CBO
Curt Herberts has served as Senior Vice President and Chief Business Officer since December 2016 and oversees Sangamo’s business functions and plans for commercialization of its therapeutics. Mr. Herberts has over 10 years of experience in commercial strategy and corporate development. He joined Sangamo in October 2010 as Director, Corporate Development & Strategy and was promoted to Senior Director in January 2012, and Vice President and Head of Corporate Development in July 2015. During this time, Sangamo established a number of collaborative agreements, including global collaborations with Shire plc, in 2012, and Biogen, Inc., in 2014. Prior to joining Sangamo, Mr. Herberts held several positions of increasing responsibility at Campbell Alliance Group, Inc., including leadership roles in the corporate development and commercial strategy practice areas. Prior to Campbell Alliance, he worked in business development, new product planning and technology transfer. Mr. Herberts holds an A.B. in Human Biology from Stanford University and a M.B.S. from Keck Graduate Institute School of Applied Life Sciences.Less
Vice President, Research
Michael Holmes, Ph.D., has served as Vice President, Research since July 2015 and currently oversees Sangamo’s research activities. He joined Sangamo in May 2001 as a Scientist and became a Team Leader in 2002, focusing on the development of novel cell-based approaches to screen compound libraries. He was promoted to Director, Therapeutic Gene Modification in 2004, and Senior Director in 2009, where he pioneered the use of ZFNs for genome editing in transformed and primary human cells, including hematopoietic stem cells. Dr. Holmes has authored over 55 publications in the field of genome editing and gene regulation, as well as numerous patents. Prior to joining Sangamo, he worked as a post-doctoral fellow in Dr. Gerald Rubin’s lab at the University of California, Berkeley. Dr. Holmes received a B.S. in Molecular Biology from the University of California, San Diego, and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.Less
President and CEO
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.Less
Vice President, Human Resources
Leslie Mesones has served as Vice President, Human Resources since January 2017 and joined Sangamo in April 2015 as a Senior Director. Ms. Mesones has over 15 years of biopharmaceutical industry experience in human resource management, talent acquisition and recruiting. From 2013-2015, she served as Director, Human Resources at Mizuho OSI, a private medical device company with over 300 employees. Prior to that she served as Director, Human Resources at Zosano Pharma, a private pharmaceutical company focused on the delivery of CNS therapeutics. Earlier in her career Ms. Mesones held positions as Senior Manager, Human Resources at Theravance BioPharma US, Inc., as a Talent Acquisition Manager at Bayer Biological Products, a Bayer manufacturing site with 1300 employees, and as the Recruiting Manager at Axys Pharmaceuticals. Ms. Mesones received a B.A. in Spanish Literature from the University of California, Davis, and received her Career & Organizational Coaching Certificate from John F. Kennedy University.Less
Vice President, Pharmacology, Toxicology and Bioanalytical Sciences
Kathleen Meyer, M.P.H., Ph.D., D.A.B.T., has served as Vice President, Pharmacology, Toxicology and Bioanalytical Sciences since January 2017, supporting the nonclinical development of Sangamo’s zinc finger protein-based genome editing and AAV-based gene therapy candidates. Dr. Meyer joined Sangamo as a Senior Director in 2014 with 20 years of industry experience in toxicology, bioanalytical development, pharmacokinetics, and nonclinical safety evaluation strategy and implementation of various biopharmaceuticals, including monoclonal antibody, enzyme replacement and gene therapies. Prior to joining Sangamo, Dr. Meyer served as Principal Scientist, Pharmacology and Toxicology at BioMarin Pharmaceutical Inc. where she guided small molecule and biologic drug candidates through the nonclinical development process, supporting clinical trials and marketing authorization. From 2009 to 2012, she served as Senior Director, Nonclinical Safety Evaluation at XOMA LLC and, prior to that, held positions as a Scientist and Principal Scientist at Elan Pharmaceuticals from 1997-2003. Before joining industry, she worked as a post-doctoral fellow evaluating non-viral methods of gene delivery in Dr. Frank Szoka Jr.’s laboratory at the University of California, San Francisco. Dr. Meyer received an A.B. in Physiology, a M.P.H. specializing in Toxicology and Epidemiology, and her Ph.D. in Environmental Health Science/Toxicology from the University of California, Berkeley. Dr. Meyer is a Diplomat of the American Board of Toxicology.Less
Vice President, Technology
Edward Rebar, Ph.D., has served as Vice President, Technology since 2008, a capacity in which he directs the lead design and optimization for our therapeutic programs. Since joining Sangamo in 1998, Dr. Rebar has held several leadership positions at the company, including Senior Director, Technology, in which he led the development of Sangamo’s zinc finger protein design platform and co-managed the Company’s partnership with Sigma Aldrich. Dr. Rebar has authored over 55 publications relating to the development of customized DNA binding proteins and nucleases for genome editing, as well as numerous patents. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.Less
Vice President, Corporate Communications and Investor Relations
McDavid Stilwell has served as Vice President, Corporate Communications and Investor Relations since November 2016. He has over 20 years of relevant experience across various business functions, including communications, investor relations, business development and financial analysis. Prior to joining Sangamo, Mr. Stilwell served as Vice President, Corporate Communications, Investor Relations & Business Development at Orexigen Therapeutics, Inc. From 2005 to 2012 he served as Director, Business Development, Corporate Communications and Financial Analysis at GTx, Inc., a development stage biopharmaceutical company. Earlier, Mr. Stilwell worked for five years as a Senior Investment Analyst for Shadwell Capital LLC, a hedge fund. Mr. Stilwell began his career as a journalist, first as a newspaper reporter and later as an executive editor of an investor newsletter covering financial services industry mergers and acquisitions. Mr. Stilwell received a B.A. in Liberal Arts from St. John’s College, Annapolis, Maryland, and a M.B.A. from Harvard Business School.Less
Senior Vice President and CFO
Kathy Yi has served as Senior Vice President and Chief Financial Officer since March 2017. Ms. Yi was formerly with Novartis Pharmaceuticals where she served as Head of Finance, Inhalation Technical Research & Development, responsible for the financial management of technical R&D organizations in California and Switzerland. Prior to joining Novartis, she was with Life Technologies Corp. from 2007 to 2014, during which time she held financial management positions of increasing seniority, including Finance Leader, Corporate FP&A. Prior to joining Life Technologies, Ms. Yi held various positions in finance at Intel Corp., from 2001 to 2007. She began her career as a Process/Project Engineer at Bechtel Corp., a leading global engineering, construction and project management company. Ms. Yi received a B.S. degree in Chemical Engineering from the University of California at Berkeley and an M.B.A. degree from Columbia Business School.Less
H. Stewart Parker has been a member of our Board of Directors since June 2014. Ms. Parker has over 30 years of experience in the biotechnology industry . She served as the chief executive officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health research institute from March 2011 to December 2013. In 1992, Ms. Parker founded Targeted Genetics Corporation, a publicly traded Seattle -based biopharmaceutical company formed to develop gene-based treatments for acquired and inherited diseases that became a world leader in AAV gene therapy. She held the position of President and CEO and was a member of its board of directors from the company's inception until November 2008. Prior to founding Targeted Genetics, Ms. Parker served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. From February 1991 to January 1993, Ms. Parker served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. She currently serves as a member of the board of directors for several for-profit and non-profit companies including C3 Jian Inc, Oncogenex Technologies Inc and IDRI and on the advisory boards of the University of Washington Foster School of Business and College of Arts & Sciences. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. From 2010 through 2013, he was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman. Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.
Executive Vice President and CBO of Horizon Pharma, plc
Robert F. Carey has served as a member of Sangamo's Board of Directors since June 2016. Mr. Carey currently serves as Executive Vice President and Chief Business Officer of Horizon Pharma, plc, a biopharmaceutical company with nine commercialized medicines though its orphan, rheumatology and primary care units. He also serves as a member of the Board of Directors of Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of personalized immuntherapies for the treatment of cancer and infectioius diseases. Before joining Horizon Pharma, he served as managing director and head of the healthcare investment banking group at JMP Securities LLC from March 2013 to March 2014. Prior to that, Mr. Carey served as a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities International, Inc. He has also held roles at Shearson Lehman Hutton and Ernst & Whinney. Mr. Carey received a B.S. in Accounting from the Univesity of Notre Dame.
Dr. Jeffs currently serves as a Senior Advisor to United Therapeutics Corp., where he worked for 18 years, most recently as President and co-CEO. He has over 25 years of experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs. While at United Therapeutics, Dr. Jeffs led the clinical development, regulatory approval and commercialization of six rare disease products. Prior to joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs currently serves as a member of the board of directors of Axsome Therapeutics and Dova Pharmaceuticals. He received a B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina.
CEO of Aimmune Therapeutics
Stephen G. Dilly, M.B.B.S., Ph.D., has served as a member of our Board of Directors since March 2010. From May 2014 he has served as CEO of Aimmune Therapeutics. Prior to that, from December 2011 to December 2012 Dr. Dilly was CEO of PhotoThera, Inc., a medical device company with a product in Phase III clinical trials for the treatment of ischemic stroke. From 2006 to 2011, Dr. Dilly served as President and Chief Executive Officer and a member of the Board of Directors of APT Pharmaceuticals, Inc. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various management positions at Genentech Inc., including Vice President of Development Sciences from 2002 to 2003. From 1988 to 1998, Dr. Dilly held various management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly currently serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. In 1982, Dr. Dilly earned his M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London in 1988.
President and CEO
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.
President and CEO of Conatus Pharmaceuticals, Inc.
Steven Mento has served as a member of our Board of Directors since May, 2005. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and CEO of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. As President, Dr. Mento had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr. Mento currently serves on the Boards of BIOCOM, the Biotechnology Organization (BIO), the BIO Health Section Governing Body, the BIO ECS Governing Body, the Donald P. Shiley BioSciences Center at SDSU Scientific Advisory Board, and Cal State San Marcos Advisory Council. Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto.
Managing Partner of Life Sciences Advisory
Saira Ramasastry has served as a member of our Board of Directors since June 2012. Since April 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice and business development solutions for life science companies. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&A), strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, the board of directors of Pain Therapeutics and Repros Therapeutics, and lead business advisor for the European Prevention of Alzheimer's Dementia (EPAD) consortium. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University as well as an M. Phil. in Management Studies from the University of Cambridge, where she is a guest lecturer for the Bioscience Enterprise Programme and serves on the Cambridge Judge Business School Advisory Council.
William R. Ringo has served as a member of our Board of Directors since April 2010. From April 2008 until his retirement in April 2010, Mr. Ringo was the Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. and was responsible for guiding Pfizer’s overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which acquired Abgenix in 2006. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. From 2001 to 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the Board of Directors after serving as interim Chief Executive Officer from June to September 2003. Mr. Ringo serves on the Board of Directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana’s life sciences research and corporate strengths in life sciences while encouraging business development in the region. In August 2014, he was appointed to the board of directors of Dermira, a specialty biopharmaceutical company focused on the development of medical dermatology products. Mr. Ringo received a B.S. in Business Administration and an M.B.A. from the University of Dayton.